Oral contraceptives and coronary heart disease: Modulation of glucose tolerance and plasma lipid risk factors by progestins

American Journal of Obstetrics and Gynecology

Volumn 158, Issue 6, 1988, Pages 1612-1620

  Crook, D ^a   Godsland, I F ^a   Wynn, V ^a  

^a Cavendish Imaging   (United Kingdom)

Author keywords

carbohydrates; coronary heart disease; lipoproteins; Oral contraceptives

Indexed keywords

GESTAGEN; ORAL CONTRACEPTIVE AGENT;

CARDIOVASCULAR DISEASE; FEMALE; GLUCOSE TOLERANCE; HUMAN; LIPID BLOOD LEVEL; PRIORITY JOURNAL; REVIEW; RISK FACTOR;

ANDROGENS; ARTERIAL OCCLUSIVE DISEASES; ARTERIOSCLEROSIS; ATHEROSCLEROSIS; BIOLOGY; CARBOHYDRATE METABOLIC EFFECTS; CARDIOVASCULAR EFFECTS; CONTRACEPTION; CONTRACEPTIVE AGENTS; CONTRACEPTIVE AGENTS, FEMALE; CONTRACEPTIVE AGENTS, PROGESTIN; CONTRACEPTIVE METHODS; DIABETES MELLITUS; DISEASES; ENDOCRINE EFFECTS; ENDOCRINE SYSTEM; ESTROGENS; FAMILY PLANNING; GLUCOSE METABOLISM EFFECTS; HEART DISEASES; HORMONES; LEVONORGESTREL; LIPID METABOLIC EFFECTS; LIPIDS; LITERATURE REVIEW; METABOLIC EFFECTS; ORAL CONTRACEPTIVES; ORAL CONTRACEPTIVES, COMBINED; ORAL CONTRACEPTIVES, LOW-DOSE; ORAL CONTRACEPTIVES, PHASIC; PHYSIOLOGY; RISK FACTORS; VASCULAR DISEASES;

CONTRACEPTIVES, ORAL, HORMONAL; CORONARY DISEASE; FEMALE; GLUCOSE; GLUCOSE TOLERANCE TEST; HUMAN; INSULIN; LIPIDS; LIPOPROTEINS, HDL CHOLESTEROL; PROGESTATIONAL HORMONES; RISK FACTORS; SUPPORT, U.S. GOV'T, P.H.S.;

EID: 0023894684     PISSN: 00029378     EISSN: None     Source Type: Journal    
DOI: 10.1016/0002-9378(88)90199-8     Document Type: Article

References (86)

1. Thromboembolic disease and the steroidal content of oral contraceptives. A report to the Committee on Safety of Drugs
2. Progestogens and cardiovascular reactions associated with oral contraceptives and a comparison of the 50- and 30-μg oestrogen preparations
3. Oral contraceptives and cardiovascular disease
4. Progestogen and arterial disease—Evidence from the Royal College of General Practitioner's Study
5. Problems in comparative longevity
6. Effect on hypertension and benign breast disease of progestogen component in combined oral contraceptives
7. Oestrogen/progestogen oral contraception and blood clotting: A long-term follow-up
8. Contraceptive steroids: Modifications of carbohydrate and lipid metabolism
9. Effects of oral contraceptives on carbohydrate metabolism
10. The effects of progestins in combined oral contraceptives with special reference to high-density lipoproteins
11. Myocardial infarction and cigarette smoking in women younger than 50 years of age
12. The epidemiology of coronary heart disease and related factors in the context of diabetes mellitus and impaired glucose tolerance
13. Glucose tolerance and coronary heart disease. Helsinki Policemen Study
14. Mortality from coronary heart disease and stroke in relation to degree of glycemia: The Whitehall Study
15. Postchallenge glucose concentration and coronary heart disease in men of Japanese ancestry. Honolulu Heart Program
16. Coronary heart disease in incidence and cardiovascular mortality in Busselton with reference to glucose and insulin concentrations
17. Relationship of plasma insulin levels to the incidence of myocardial infarction and coronary heart disease mortality in a middle-aged population
18. Plasma insulin as coronary heart disease risk factor: relationship to other risk factors and predictive value during 9 1/2 year follow-up of the Helsinki Policement Study population
19. Insulin and atheroma—an update
20. Evidence for an independent relationship between plasma insulin and concentration of high density lipoprotein cholesterol and triglyceride
21. Abnormalities of carbohydrate and lipid metabolism in patients with hypertension
22. Reproducibility of oral glucose tolerance data in normal and mildly diabetic subjects
23. Insulin metabolism and degradation
24. Proinsulin and C-peptide concentrations in human portal and peripheral blood
25. C-peptide metabolism and the liver
26. Assessment of insulin sensitivity in vivo
27. Metabolic risk factors for coronary heart disease in women: perspective from The Framingham Study
28. High density lipoprotein as a protective factor against coronary heart disease. The Framingham Study
29. Ischaemic heart-disease in relation to fasting values of plasma triglycerides and cholesterol. Stockholm prospective study
30. Protein-lipid relationships in human plasma in atherosclerosis and related conditions
31. Plasma-high-density-lipoprotein concentration and development of ischaemic heart disease
32. The Troms Heart study. High-density lipoprotein and coronary heart-disease: a prospective case-control study
33. HDL cholesterol and other lipids in coronary heart disease: The cooperative lipoprotein phenotyping study
34. Intra-individual variation: Significant changes in parameters of lipid and carbohydrate metabolism in the individual and intra-individual variation in different test populations
35. Variability of plasma lipids and lipoproteins: The Jerusalem Lipid Research Clinic Study
36. Effect of posture on the plasma cholesterol level
37. Interpretation of plasma lipid and lipoprotein measurements
38. Problems associated with lipid and lipoprotein analysis
39. Factors affecting the results of serum cholesterol determinations: an interlaboratory evaluation
40. Analytical performance and comparability of the determination of cholesterol by 12 Lipid Research Clinics
41. Comparison of current methods for high-density lipoprotein cholesterol
42. Laboratory measurement of HDL
43. Relation of angiographically defined coronary artery disease to plasma lipoprotein subfractions and apolipoproteins
44. High density and low density lipoprotein subfractions in survivors of myocardial infarction and in control subjects
45. The association of serum lipids, lipoproteins and apolipoproteins with coronary heart disease as assessed by coronary arteriography
46. Ischemic heart disease, atherosclerosis and longevity
47. Effects of low-dose oral contraceptives on serum lipids and lipoproteins: differential changes in high-density lipoprotein subclasses
48. Separation and quantitation of subclasses of human plasma high density lipoproteins by a simple precipitation procedure
49. Analysis of high density lipoprotein subclasses by a precipitation procedure: Comparison with preparative ultracentrifuge
50. The distribution and chemical composition of ultracentrifugally separated lipoproteins and human serum
51. Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge
52. A comparison of methods for the estimation of plasma low- and very-low-density lipoprotein cholesterol. The LRC Prevalence Study
53. Relationships of gender, sex hormone use, and age with lipoprotein cholesterol/triglyceride ratios in an adult population
54. International survey of apolipoproteins AI and B measurements (1983–1984)
55. High-density lipoprotein apolipoprotein metabolism
56. Measurement of androgenicity. The spectrum of progestogen activity
57. Progestational potency of oral contraceptives
58. Oral contraceptives in the United States: trends in content and potency
59. Chlormadinone contraceptive withdrawn
60. Comparison of effects of different combined oral-contraceptive formulations on carbohydrate and lipid metabolism
61. Sex, gonadal steroids and plasma lipoproteins: prevailing assumptions and unanswered questions
62. The influence of androgens on insulin resistance
63. Some effects of oral contraceptives on serum lipid and lipoprotein levels
64. The influence of oral contraceptive formulation on carbohydrate and lipid metabolism
65. Norethindrone acetate, postheparin ipolytic activity and plasma triglycerides in familial types I, II, IV, and V hyperlipoproteinemia
66. Divergent effects of d-norgestrel on the metabolism of rat very low density and low density apolipoprotein B
67. Oral glucose tolerance and the potency of contraceptive progestins
68. Effect of duration of low-dose oral contraceptive administration on carbohydrate metabolism
69. Effect of an oral contraceptive agent on plasma lipids, plasma lipoproteins, the intravenous fat tolerance test and the post-heparin lipoprotein activity
70. Progestins and oral contraceptive-induced lipoprotein changes: a prospective study
71. Distribution of lipoprotein triglyceride and lipoprotein cholesterol in an adult population by age, sex and hormone use
72. Effect of estrogen/progestin potency on lipid/lipoprotein cholesterol
73. Serum high-density-lipoprotein cholesterol in women using oral contraceptives, estrogens and progestins
74. Effects of oral contraceptives on lipoprotein triglyceride and cholesterol: relationship to estrogen and progestin potency
75. Effects of oral contraceptives on lipoprotein lipids: a prospective study
76. The serum lipoprotein transport system in health, metabolic disorders, atherosclerosis and coronary heart disease
77. Multiphasic oral contraceptives: Efficacy and metabolic impact
78. Oral contraception and insulin sensitivity: In vivo assessment in normal women and women with previous gestational diabetes
79. A randomized prospective study of the metabolic effects of four low-estrogen oral contraceptives
80. Comparative effects of monophasic desogestrel plus ethinoestradiol and triphasic levonorgestrel plus ethinyloestradiol on lipid metabolism
81. A randomized crossover comparison of two low-dose contraceptives: Effects on serum lipids and lipoproteins
82. The effect of triphasic and biphasic oral contraceptive preparations on HDL-cholesterol and LDL-cholesterol in young women
83. Effects of seven low dose combined oral contraceptives on high density lipoprotein subfractions
84. Oral contraceptives, lipids and cardiovascular disease
85. Metabolic effects of a biphasic oral contraceptive preparation containing ethinyloestradiol and desogestrel on serum lipoproteins and apolipoproteins